139 related articles for article (PubMed ID: 31079495)
1. Development of R
Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
[TBL] [Abstract][Full Text] [Related]
2. Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer.
Wang X; Cheng L; Xie HJ; Ju RJ; Xiao Y; Fu M; Liu JJ; Li XT
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1154-1169. PubMed ID: 30043652
[TBL] [Abstract][Full Text] [Related]
3. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
[TBL] [Abstract][Full Text] [Related]
4. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
5. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer.
Xie HJ; Zhao J; Zhuo-Ma D; Zhan-Dui N; Er-Bu A; Tsering T
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3465-3477. PubMed ID: 31432702
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC.
Kong L; Zhang SM; Chu JH; Liu XZ; Zhang L; He SY; Yang SM; Ju RJ; Li XT
Int J Nanomedicine; 2020; 15():6451-6468. PubMed ID: 32922011
[TBL] [Abstract][Full Text] [Related]
9. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X
Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668
[No Abstract] [Full Text] [Related]
11. Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer.
Ju RJ; Cheng L; Peng XM; Wang T; Li CQ; Song XL; Liu S; Chao JP; Li XT
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):616-628. PubMed ID: 29381101
[TBL] [Abstract][Full Text] [Related]
12. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells.
Wang YJ; Tang L; Lu XH; Liu JT; Wang YY; Geng HX; Li XT; An Q
J Liposome Res; 2023 Jun; 33(2):197-213. PubMed ID: 36440599
[TBL] [Abstract][Full Text] [Related]
14. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.
Biswas S; Deshpande PP; Perche F; Dodwadkar NS; Sane SD; Torchilin VP
Cancer Lett; 2013 Jul; 335(1):191-200. PubMed ID: 23419527
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small-cell lung cancer.
An Q; Shi CX; Guo H; Xie SM; Yang YY; Liu YN; Liu ZH; Zhou CZ; Niu FJ
Pharm Dev Technol; 2019 Nov; 24(9):1164-1174. PubMed ID: 31340709
[TBL] [Abstract][Full Text] [Related]
16. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
[TBL] [Abstract][Full Text] [Related]
17. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer.
Liu L; Mu LM; Yan Y; Wu JS; Hu YJ; Bu YZ; Zhang JY; Liu R; Li XQ; Lu WL
Int J Nanomedicine; 2017; 12():4163-4176. PubMed ID: 28615943
[TBL] [Abstract][Full Text] [Related]
18. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
[TBL] [Abstract][Full Text] [Related]
19. Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.
Liu K; Dai L; Li C; Liu J; Wang L; Lei J
Sci Rep; 2016 Jul; 6():29461. PubMed ID: 27377918
[TBL] [Abstract][Full Text] [Related]
20. PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.
Ju RJ; Cheng L; Xiao Y; Wang X; Li CQ; Peng XM; Li XT
J Liposome Res; 2018 Sep; 28(3):236-248. PubMed ID: 28480778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
